Multikinase inhibitors use in differentiated thyroid carcinoma
Sina Jasim,1,* Levent Ozsari,2,* Mouhammed Amir Habra2 1Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, USA; 2Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA *These authors con...
Guardado en:
Autores principales: | Jasim S, Ozsari L, Habra MA |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a7502555b4a34c08a0e8a768baff9287 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Emerging role of multikinase inhibitors for refractory thyroid cancer
por: Perez CA, et al.
Publicado: (2012) -
Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
por: Stjepanovic N, et al.
Publicado: (2014) -
DNAJB11 predicts a poor prognosis and is associated with immune infiltration in thyroid carcinoma: a bioinformatics analysis
por: Rongxin Sun, et al.
Publicado: (2021) -
Anaplastic thyroid carcinoma - current issues of today (according to NCCN Guidelines)
por: O.O. Halay, et al.
Publicado: (2019) -
Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
por: Iason Psilopatis, et al.
Publicado: (2021)